TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Efficacy of Melatonin in Sleep Problems of Hemodialysis and Peritoneal Dialysis Patients
Brief Summary: Sleep problems can lead to a bad quality of life and a raise of morbidity, also in dialysis patients. Sleep problems can be caused by a disturbance of circadian rhythms in our body. For a good regulation of these circadian rhythms a uniform external synchronisation is necessary. This is the synchronisation of the biological clock of our body by light and other influences. In case of a disturbance of the external synchronisation, due to for example naps during the day or wake periods at night, internal rhythms can be unlinked. As a result a weakened melatonin rhythm and a problematic sleep-wake cycle can be observed. Most dialysis patients have sleep problems. Their sleep latency is prolonged. They often take a nap during the day and their sleep efficiency is poor. There has only been one study on the melatonin rhythm of dialysis patients. The conclusion of this study was that the melatonin rhythm of dialysis patients is weakened and disturbed, probably caused by renal insufficiency. In this study no link was made between melatonin rhythm and the nature and severity of possible sleep problems. In different studies with non-dialysis patients and a disturbed melatonin rhythm, exogenous melatonin at the right time leads to a recovery of the normal rhythm and the normal biological clock and a better quality of life.

The aim is to research the endogenous melatonin rhythm and to improve sleep problems of hemodialysis patients with a placebo-controlled study with exogenous melatonin. Next to this a substudy is performed, in which the effect of the change of daytime to nocturnal in hospital hemodialysis on sleep and melatonin is researched.


Options:
A: Arm Label: extended hours; Type: EXPERIMENTAL; Interventions: Procedure: haemodialysis | Arm Label: standard hours; Type: ACTIVE_COMPARATOR; Interventions: Procedure: haemodialysis | Intervention Type: PROCEDURE; Name: haemodialysis; Assigned to Arm(s): extended hours, standard hours
B: Arm Label: tMBSR; Type: EXPERIMENTAL; Interventions: Behavioral: tMBSR | Arm Label: Support Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Support group | Intervention Type: BEHAVIORAL; Name: tMBSR; Assigned to Arm(s): tMBSR | Intervention Type: BEHAVIORAL; Name: Support group; Assigned to Arm(s): Support Group
C: Arm Label: Dopamine Agonist Group; Type: EXPERIMENTAL; Interventions: Other: Dopamine Agonist and Exercise | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Other: Dopamine Agonist and Exercise | Intervention Type: OTHER; Name: Dopamine Agonist and Exercise; Assigned to Arm(s): Dopamine Agonist Group, Placebo Group
D: Intervention Type: DRUG; Name: Melatonin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Changes in Inflammatory Markers in Induced Sputum Following Treatment With Tiotropium Inhalation Capsules 18mcg Once Daily in Patients With Chronic Obstructive Pulmonary Disease
Brief Summary: Patients with COPD experience exacerbations that are a major cause of morbidity. Exacerbations are associated with increased airway and systemic inflammation and those experiencing frequent exacerbations demonstrate increased inflammation in the stable state. Tiotropium has been shown to reduce exacerbation frequency and it might be postulated that this is due to a reduction in inflammation. The study will compare airway inflammation and exacerbation frequency in patients with COPD on tiotropium or placebo.


Options:
A: Arm Label: Tiotropium Respimat 5mcg (Tio R5); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Tiotropium Respimat 10mcg (Tio R10); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Tiotropium Inhalation Solution; Assigned to Arm(s): Tiotropium Respimat 10mcg (Tio R10), Tiotropium Respimat 5mcg (Tio R5) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: tiotropium; Type: EXPERIMENTAL; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis
Brief Summary: The objective of this trial is to determine the safety and effect on pulmonary function of 14 days of inhaled L-arginine versus placebo administered over a period of 14 days in a cohort of CF patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
B: Arm Label: Active Treatment Group; Type: EXPERIMENTAL; Interventions: Drug: Active Treatment Group 7% Hypertonic Saline | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Control Group 0.9% Isotonic Saline | Intervention Type: DRUG; Name: Active Treatment Group 7% Hypertonic Saline; Assigned to Arm(s): Active Treatment Group | Intervention Type: DRUG; Name: Control Group 0.9% Isotonic Saline; Assigned to Arm(s): Control Group
C: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A
D: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis
Brief Summary: The objective of this trial is to determine the safety and effect on pulmonary function of 14 days of inhaled L-arginine versus placebo administered over a period of 14 days in a cohort of CF patients.


Options:
A: Arm Label: 7% saline; Type: EXPERIMENTAL; Interventions: Drug: 7% saline | Arm Label: 0.12% saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.12% saline | Intervention Type: DRUG; Name: 0.12% saline; Assigned to Arm(s): 0.12% saline | Intervention Type: DRUG; Name: 7% saline; Assigned to Arm(s): 7% saline
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: hypertonic saline (7 %) and isotonic saline (0.9%) | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: hypertonic saline (7 %) and isotonic saline (0.9%); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis
Brief Summary: The objective of this trial is to determine the safety and effect on pulmonary function of 14 days of inhaled L-arginine versus placebo administered over a period of 14 days in a cohort of CF patients.


Options:
A: Arm Label: ACTs after HTS inhalation:; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Arm Label: ACTs during HTS inhalation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Airways clearance and Hypertonic saline inhalation | Intervention Type: PROCEDURE; Name: Airways clearance and Hypertonic saline inhalation; Assigned to Arm(s): ACTs after HTS inhalation:, ACTs during HTS inhalation
B: Arm Label: 7% saline; Type: EXPERIMENTAL; Interventions: Drug: 7% saline | Arm Label: 0.12% saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0.12% saline | Intervention Type: DRUG; Name: 0.12% saline; Assigned to Arm(s): 0.12% saline | Intervention Type: DRUG; Name: 7% saline; Assigned to Arm(s): 7% saline
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
D: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis
Brief Summary: The objective of this trial is to determine the safety and effect on pulmonary function of 14 days of inhaled L-arginine versus placebo administered over a period of 14 days in a cohort of CF patients.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: KB001 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: KB001; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
B: Arm Label: Antioxidant-enriched multivitamin supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: AquADEK | Intervention Type: DIETARY_SUPPLEMENT; Name: AquADEK; Assigned to Arm(s): Antioxidant-enriched multivitamin supplement
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
D: Arm Label: Treatment A; Type: EXPERIMENTAL; Interventions: Drug: SB656933 | Arm Label: Treatment B; Type: EXPERIMENTAL; Interventions: Drug: SB656933 | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SB656933; Assigned to Arm(s): Treatment A | Intervention Type: DRUG; Name: SB656933; Assigned to Arm(s): Treatment B | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pilot Study of the Short Term Safety and Efficacy of Inhaled L-arginine in Patients With Cystic Fibrosis
Brief Summary: The objective of this trial is to determine the safety and effect on pulmonary function of 14 days of inhaled L-arginine versus placebo administered over a period of 14 days in a cohort of CF patients.


Options:
A: Intervention Type: DRUG; Name: hypertonic saline; Assigned to Arm(s): N/A
B: Arm Label: Active treatment group; Type: EXPERIMENTAL; Interventions: Drug: 7% Hypertonic Saline (HS) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS) | Intervention Type: DRUG; Name: 7% Hypertonic Saline (HS); Assigned to Arm(s): Active treatment group | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS); Assigned to Arm(s): Control group
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: L-arginine | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: L-arginine; Assigned to Arm(s): 2
D: Arm Label: sodium chloride 6%; Type: EXPERIMENTAL; Interventions: Drug: sodium chloride 6% | Arm Label: sodium chloride 0,9%; Type: PLACEBO_COMPARATOR; Interventions: Drug: sodium chloride 0,9% | Intervention Type: DRUG; Name: sodium chloride 6%; Assigned to Arm(s): sodium chloride 6% | Intervention Type: DRUG; Name: sodium chloride 0,9%; Assigned to Arm(s): sodium chloride 0,9%

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)
Brief Summary: In this 2-year, multisite, randomized, placebo-controlled trial involving 607 children with vesicoureteral reflux that was diagnosed after a first or second febrile or symptomatic urinary tract infecton, we evaluated the efficacy of Trimethoprim-Sulfamethoxazole (TMP-SMZ) prophylaxis in preventing recurrences (primary outcome). Secondary outcomes were renal scarring, treatment failure (a composite of recurrences and scarring), and antimicrobial resistance.


Options:
A: Arm Label: sulfamethoxazole/trimethoprim; Type: EXPERIMENTAL; Interventions: Drug: Sulfamethoxazole/trimethoprim | Arm Label: No prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfamethoxazole/trimethoprim; Assigned to Arm(s): sulfamethoxazole/trimethoprim
B: Intervention Type: DRUG; Name: oral amoxicilline/clavulanic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iv ceftriaxone; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: antibiotic to reduce the recurrence of infection; Assigned to Arm(s): N/A
D: Arm Label: Trimethoprim-Sulfamethoxazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-Sulfamethoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trimethoprim-Sulfamethoxazole; Assigned to Arm(s): Trimethoprim-Sulfamethoxazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)
Brief Summary: In this 2-year, multisite, randomized, placebo-controlled trial involving 607 children with vesicoureteral reflux that was diagnosed after a first or second febrile or symptomatic urinary tract infecton, we evaluated the efficacy of Trimethoprim-Sulfamethoxazole (TMP-SMZ) prophylaxis in preventing recurrences (primary outcome). Secondary outcomes were renal scarring, treatment failure (a composite of recurrences and scarring), and antimicrobial resistance.


Options:
A: Arm Label: Trimethoprim-Sulfamethoxazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trimethoprim-Sulfamethoxazole | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trimethoprim-Sulfamethoxazole; Assigned to Arm(s): Trimethoprim-Sulfamethoxazole | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: antibiotic to reduce the recurrence of infection; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: oral amoxicilline/clavulanic acid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: iv ceftriaxone; Assigned to Arm(s): N/A
D: Arm Label: sulfamethoxazole/trimethoprim; Type: EXPERIMENTAL; Interventions: Drug: Sulfamethoxazole/trimethoprim | Arm Label: No prophylaxis; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Sulfamethoxazole/trimethoprim; Assigned to Arm(s): sulfamethoxazole/trimethoprim

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Role of Topical Prednisolone Acetate Following Selective Laser Trabeculoplasty
Brief Summary: To evaluate whether or not using topical steroids after selective laser trabeculoplasty affects intraocular pressure outcomes.


Options:
A: Intervention Type: DRUG; Name: prednisolone acetate 1%; Assigned to Arm(s): N/A
B: Arm Label: Argon laser trabeculoplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Argon laser trabeculoplasty, Procedure: Selective laser trabeculoplasty | Arm Label: selective laser trabeculoplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Argon laser trabeculoplasty, Procedure: Selective laser trabeculoplasty | Intervention Type: PROCEDURE; Name: Argon laser trabeculoplasty; Assigned to Arm(s): Argon laser trabeculoplasty, selective laser trabeculoplasty | Intervention Type: PROCEDURE; Name: Selective laser trabeculoplasty; Assigned to Arm(s): Argon laser trabeculoplasty, selective laser trabeculoplasty
C: Arm Label: Direct Selective Trabeculoplasty; Type: EXPERIMENTAL; Interventions: Device: Direct Selective Trabeculoplasty | Arm Label: Selective Trabeculoplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: Selective Trabeculoplasty | Intervention Type: DEVICE; Name: Direct Selective Trabeculoplasty; Assigned to Arm(s): Direct Selective Trabeculoplasty | Intervention Type: DEVICE; Name: Selective Trabeculoplasty; Assigned to Arm(s): Selective Trabeculoplasty
D: Arm Label: Selective laser trabeculoplasty; Type: EXPERIMENTAL; Interventions: Device: Selective laser trabeculoplasty | Arm Label: Travoprost; Type: ACTIVE_COMPARATOR; Interventions: Drug: Travoprost | Intervention Type: DEVICE; Name: Selective laser trabeculoplasty; Assigned to Arm(s): Selective laser trabeculoplasty | Intervention Type: DRUG; Name: Travoprost; Assigned to Arm(s): Travoprost

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Clinical Trial to Assess the Efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) in the Management of Type 1 Diabetes
Brief Summary: Subjects with intensively-treated type 1 diabetes and glycated hemoglobin (HbA1c) 7.0%-10.0% in 3 age groups (\>25, 15-24, 8-14) will be randomized to a continuous glucose monitoring (CGM) group or control group. The primary outcome is change in HbA1c after 26 weeks. A parallel randomized trial is being conducted for a second cohort with HbA1c \<7.0% that will follow an identical protocol to that of the first cohort with HbA1c \>=7.0%.

The \>=7.0% trial was specifically designed and statistically powered to compare separately the impact of continuous versus standard intensive glucose monitoring in the three age groups. Both trials used standardized treatment algorithms and equivalent frequent contacts with subjects in both the CGM and control group.

After completion of the 26-week trial, the CGM group continues to use CGM for another 26 weeks to evaluate whether any beneficial effect seen in the first 6 months is sustained with longer-term use and less intensive contact and the control group initiates CGM use with less intensive contact after the first month than was provided at initiation of CGM use in the CGM group in the randomized trial.


Options:
A: Arm Label: A,1; Type: NO_INTERVENTION; Interventions: Device: Real time access to current glucose values during CGMS | Arm Label: A,2; Type: NO_INTERVENTION; Interventions: Device: Real time access to current glucose values during CGMS | Intervention Type: DEVICE; Name: Real time access to current glucose values during CGMS; Assigned to Arm(s): A,1, A,2
B: Arm Label: Open; Type: EXPERIMENTAL; Interventions: Device: Real-Time Continuous Glucose monitoring System (RT-CGMS) | Arm Label: Blind; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Real-Time Continuous Glucose monitoring System (RT-CGMS); Assigned to Arm(s): Open
C: Arm Label: 722 sensor augmented pump; Type: EXPERIMENTAL; Interventions: Device: MiniMed Paradigm REAL-Time System | Arm Label: Multiple Daily Injections (MDI); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MiniMed Paradigm REAL-Time System; Assigned to Arm(s): 722 sensor augmented pump
D: Arm Label: Standard intensive glucose monitoring; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Continuous Glucose Monitoring (CGM); Type: ACTIVE_COMPARATOR; Interventions: Device: Continuous glucose monitor | Intervention Type: DEVICE; Name: Continuous glucose monitor; Assigned to Arm(s): Continuous Glucose Monitoring (CGM)

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Artemisinin combination therapies (ACT) are currently recommended for malaria treatment. Artemether-lumefantrine(A-L) and Artesunate+amodiaquine (A+A) have been the most commonly adopted of the recommended ACT regimens. In Ghana, A+A is the current first-line antimalarial treatment in Ghana, but there has been 1 efficacy report of this regimen in Ghana till date. Moreover, the safety of repeated treatments with ACT has been little studied. This study aims to evaluate the efficacy of A+A vs. A-L, as well as the safety of repeated treatments of these regimens in a longitudinal trial in which recruited children will be followed up for 1 year.


Options:
A: Intervention Type: DRUG; Name: amodiaquine+artesunate/artemether-lumefantrine; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Artekin / Coartemther; Assigned to Arm(s): N/A
C: Arm Label: Dihydroartemisin-piperaquine; Type: EXPERIMENTAL; Interventions: Drug: Dihydroartemisin-piperaquine | Arm Label: Mefloquine + Artesunate (MAS3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Mefloquine + Artesunate | Intervention Type: DRUG; Name: Dihydroartemisin-piperaquine; Assigned to Arm(s): Dihydroartemisin-piperaquine | Intervention Type: DRUG; Name: Mefloquine + Artesunate; Assigned to Arm(s): Mefloquine + Artesunate (MAS3)
D: Intervention Type: DRUG; Name: artesunate-amodiaquine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: coartem; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: artesunate-lapdap; Assigned to Arm(s): N/A

Answer: A